The European Union drug regulator on Monday approved the use of the Covid-19 vaccine from US-based Novavaks in 18 years and above, paving the way for the fifth shot in the region as an Omicron variant spread.
Data from two large studies showed the vaccine had an efficacy of around 90%, said the European Medicine Agency, added that there was currently limited data about its efficacy of several variants that were concerned, including Omicron.
“After a thorough evaluation, the Ema Human Medicine Committee (CHMP) concluded by the consensus that the data on the vaccine faced by the rump with a soaring infection, EMA has accelerated other shots.
Protein-based vaccines Novavax uses alternative technology to four other shots, which makes it more interesting The EU for trying to diversify its vaccine portfolio.
The company has around eight manufacturing locations, including those from the Indian Serum Institute, the largest vaccine maker in the world.
The production of shots in India was also approved by EMA, said an EU official.
On Friday , which issued an emergency use for the version of the SII Novavax vaccine
The EU regulator supports Novavax Shot as the 5th Vax Covid in the region
